Valneva Se SEC Filings

Valneva SE filed a Form 6-K reporting that it has released its results for the three months ended September 30, 2025. The company furnished a press release and unaudited interim condensed consolidated financial statements as exhibits, providing more detail on its recent quarterly performance.

Most of the information in this Form 6-K, excluding the section titled “Financial Outlook” in the press release, is incorporated by reference into Valneva’s existing Form F-3 registration statement. This means those disclosures can now be used in connection with Valneva’s registered securities offerings in the United States.

Valneva SE entered a senior term loan facility totaling $500.0M, split into a committed $215.0M Tranche A expected to fund around Oct 17, 2025 and up to $285.0M of uncommitted subsequent tranches available with lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement in full; subsequent tranches are reserved for general corporate and working capital needs.

The Term Loans mature five years after each funding date, carry a fixed interest rate of 9.00% per annum with quarterly payments, and include an upfront fee of 2.00% of principal at each funding. Prepayments are permitted but subject to a premium up to 3.00% depending on timing. Separately, the company reconfirmed its Phase 3 Lyme vaccine trial remains on track, with Pfizer targeting BLA and MAA submissions in 2026, VALOR trial outcomes expected in H1 2026, and a contemplated launch in H2 2027 pending approval.

Valneva SE entered a senior term loan facility for an aggregate $500.0M, split into a $215.0M committed Tranche A (expected funded ~Oct 17, 2025) and up to $285.0M of uncommitted subsequent tranches subject to lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement; subsequent tranches are designated for general corporate and working capital including business development and permitted acquisitions. The loans mature five years after each tranche funding and carry a fixed interest rate of 9.00% with quarterly payments. There is a funding fee equal to 2.00% of principal and prepayment premiums of 3.00% if repaid before the third anniversary and 2.00% thereafter. Separately, Valneva reconfirms its Phase 3 Lyme vaccine trial remains on track; Pfizer targets BLA and MAA submissions in 2026 if data are positive, with VALOR outcomes expected in H1 2026 and a potential Pfizer launch in H2 2027.

Bpifrance Participations, EPIC Bpifrance, Bpifrance S.A., Caisse des de9pf4ts et consignations (CDC) and CDC Croissance filed Amendment No. 3 to their Schedule 13D reporting positions in Valneva SE ordinary shares.

The filing shows Bpifrance Participations directly holds 8,639,886 ordinary shares and 17,259,364 voting rights; CDC Croissance holds 4,550,812 ordinary shares and voting rights. Aggregate voting rights reported for certain Reporting Persons are higher due to indirect holdings and joint ownership structures, with CDC reported as holding 21,810,176 voting rights. The percentages are calculated on 171,730,534 ordinary shares outstanding and 187,854,877 voting rights under U.S. law, producing a 9.2% voting-rights stake for Bpifrance Participations and an 11.6% voting-rights stake for CDC.

The Reporting Persons state the shares were acquired for investment purposes and that the apparent reduction in their percentage ownership results solely from an increase in outstanding shares, not from sales by the Reporting Persons. No reportable transactions occurred in the last 60 days and no plans currently exist for the corporate actions listed in Schedule 13D instructions, though they reserve the right to change investment intent.